MicroRNAs in the failing heart – Novel therapeutic targets?

References

• Mcmurray JJ V, Pfeffer MA. Heart failure. Lancet. 2005;365:1877–89.
   PubMed Web of Science ®Google Scholar
• Bui A, Horwich T, Fonarow G. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2010;8:30–41.
   PubMed Web of Science ®Google Scholar
• Clark MB, Amaral PP, Schlesinger FJ, Dinger ME, Taft RJ, Rinn JL, et al. The reality of pervasive transcription. PLoS Biol. 2011;9:e1000625.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436:214–20.
   PubMed Web of Science ®Google Scholar
• Kwon C, Han Z, Olson EN, Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci U S A. 2005;102: 18986–91.
   PubMed Web of Science ®Google Scholar
• Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A. 2008;105:2111–6.
   PubMed Web of Science ®Google Scholar
• Rao PK, Toyama Y, Chiang R, Gupta S, Bauer M, Medvid R, et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res. 2009; 105:585–94.
   PubMed Web of Science ®Google Scholar
• Chien KR. Stress pathways and heart failure minireview. Cell. 1999;98:555–8.
   PubMed Web of Science ®Google Scholar
• Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109: 1580–9.
   PubMed Web of Science ®Google Scholar
• Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, Van Laake LW, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116:258–67.
   PubMed Web of Science ®Google Scholar
• Naga Prasad SV, Duan Z, Gupta MK, Surampudi VSK, Volinia S, Calin GA, et al. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem. 2009;284:27487–99.
   PubMed Web of Science ®Google Scholar
• Krenz M, Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol. 2004;44:2390–7.
   PubMedGoogle Scholar
• Van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316:575–9.
   PubMed Web of Science ®Google Scholar
• Van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103:18255–60.
   PubMed Web of Science ®Google Scholar
• Gurha P, Abreu-Goodger C, Wang T, Ramirez MO, Drumond AL, Van Dongen S, et al. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation. 2012;125:2751–61.
   PubMed Web of Science ®Google Scholar
• Huang Z-P, Chen J, Seok H, Zhang Z, Kataoka M, Hu X, Wang DZ. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res. 2013;112: 1234–43.
   PubMed Web of Science ®Google Scholar
• Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. 2012;3:1078.
   PubMed Web of Science ®Google Scholar
• Mann DL. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res. 2002;91:988–98.
   PubMed Web of Science ®Google Scholar
• Heymans S, Corsten MF, Verhesen W, Carai P, Van Leeuwen REW, Custers K, et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013;128:1420–32.
   PubMed Web of Science ®Google Scholar
• Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunol Rev. 2013;253:146–57.
   PubMed Web of Science ®Google Scholar
• Seok HY, Chen J, Kataoka M, Huang Z-P, Ding J, Yan J, et al. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res. 2014;114:1585–95.
   PubMed Web of Science ®Google Scholar
• Van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012;11:860–72.
   PubMed Web of Science ®Google Scholar
• Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980–4.
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124:1537–47.
   PubMed Web of Science ®Google Scholar
• Callis TE, Pandya K, Seok HY, Tang R-H, Tatsuguchi M, Huang Z-P, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009;119:2772–86.
   PubMed Web of Science ®Google Scholar
• Bernardo BC, Nguyen SS, Winbanks CE, Gao X-M, Boey EJH, Tham YK, et al. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J. 2014;28:1–14.
   PubMedGoogle Scholar
• Jessup M, Greenberg, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304–13.
   PubMed Web of Science ®Google Scholar
• Wahlquist C, Jeong D, Rojas-Munoz A, Kho C, Lee A, Mitsuyama S, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature. 2014;508:531–5.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–7.
   PubMed Web of Science ®Google Scholar
• Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55:1977–83.
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Zeiher AM. Circulating microRNAs: novel biomarkers for cardiovascular diseases? Eur Heart J. 2010; 31:2705–7.
   PubMed Web of Science ®Google Scholar
• Gidlöf O, Andersson P, Van der Pals J, Götberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology. 2011;118:217–26.
   PubMed Web of Science ®Google Scholar
• Tijsen AJ, Creemers EE, Moerland PD, De Windt LJ, Van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106: 1035–9.
   PubMed Web of Science ®Google Scholar
• Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14:147–54.
   PubMed Web of Science ®Google Scholar
• Bauters C, Kumarswamy R, Holzmann A, Bretthauer J, Anker SD, Pinet F, et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol. 2013;168: 1837–40.
   PubMed Web of Science ®Google Scholar
• Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3:499–506.
   PubMed Web of Science ®Google Scholar
• Gidlöf O, Smith JG, Miyazu K, Gilje P, Spencer A, Blomquist S, et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc Disord. 2013;13:12.
   PubMedGoogle Scholar
• Fukushima Y, Nakanishi M, Nonogi H, Goto Y, Iwai N. Assessment of plasma miRNAs in congestive heart failure. Circ J. 2011;75:336–40.
   PubMed Web of Science ®Google Scholar
• Vogel B, Keller A, Frese KS, Leidinger P, Sedaghat- Hamedani F, Kayvanpour E, et al. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. Eur Heart J. 2013;34:2812–22.
   PubMed Web of Science ®Google Scholar
• Leung AKL, Sharp PA. MicroRNA functions in stress responses. Mol Cell. 2010;40:205–15.
   PubMed Web of Science ®Google Scholar
• Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368:1685–94.
   PubMed Web of Science ®Google Scholar